Condition
Hepatic Ascites
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (2)
P 3 (1)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05179265Phase 1CompletedPrimary
Recombinant Human Serum Albumin in Healthy Subjects
NCT05249374Phase 1CompletedPrimary
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
NCT06911554Phase 3CompletedPrimary
A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites
NCT06411743Phase 2CompletedPrimary
Phase II/III of Recombinant Human Albumin Injection
NCT04785755Phase 2CompletedPrimary
Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites
Showing all 5 trials